Image-Guided Radiation Therapy (IGRT) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Image-Guided Radiation Therapy (IGRT) is an advanced radiotherapy delivery approach in which medical imaging is performed immediately before (and in some systems, during) each radiation treatment fraction to verify the position of the tumour and surrounding anatomy relative to the planned treatment position. This imaging-verification step allows the radiation therapist and radiation oncologist to detect and correct any positional errors before the therapeutic beam is delivered, substantially reducing the margin of error compared with earlier radiation techniques that relied on bony landmarks or external skin tattoos alone.

The need for IGRT arises from a well-recognised limitation of all external beam radiotherapy: the position of internal organs and tumours shifts from day to day (inter-fraction motion) and even within a single treatment session (intra-fraction motion) due to respiratory movement, bladder and rectal filling, and patient repositioning variability. These positional uncertainties historically required the addition of safety margins around the clinical target volume (CTV) to create the planning target volume (PTV) — margins wide enough to ensure the tumour received the prescribed dose on every fraction regardless of positional variation. Wide PTV margins, however, mean that more normal tissue is irradiated, limiting the dose that can safely be delivered to the tumour and increasing the risk of late toxicity to adjacent critical structures.

IGRT addresses this by replacing assumptions with direct verification. With daily imaging, the actual tumour position is confirmed before each fraction; if a positional error is detected, the treatment couch is shifted to correct the offset before the beam is activated. This shift-and-treat workflow, enabled by IGRT, allows PTV margins to be reduced from the historical standard of 8–15 mm (used in conventional 3D-CRT without daily imaging) to 3–5 mm in most sites, sparing substantially more normal tissue and enabling dose escalation to the tumour. IGRT is now a standard component of virtually all modern radical radiotherapy courses for solid tumours and is considered essential infrastructure for stereotactic body radiation therapy (SBRT) and radiosurgery (SRS).

IGRT is applicable to any external beam radiotherapy course where inter-fraction or intra-fraction positional variation of the tumour is clinically significant. Its greatest impact is in tumour sites where the target moves substantially relative to bony landmarks or where the therapeutic dose must be escalated while strictly limiting doses to adjacent critical structures:

• Prostate Cancer: The prostate gland undergoes clinically significant positional variation (up to 10–15 mm anteroposteriorly) driven by rectal and bladder filling between fractions. IGRT with daily fiducial marker tracking or Calypso GPS transponders has enabled dose escalation from 70 Gy (3D-CRT era) to 78–80 Gy (IMRT with IGRT) with demonstrated reduction in late rectal toxicity (DUTCH randomised trial), and enables ultra-hypofractionated SBRT regimens (36.25 Gy in 5 fractions, as validated in PACE-B, HYPO-RT-PC trials).
• Lung Cancer: Tumour motion with respiration (up to 2–3 cm for lower lobe lesions) is the principal challenge in lung radiotherapy. IGRT with 4D-CT-based motion assessment during simulation, combined with respiratory gating, breath-hold techniques, or real-time tracking enables delivery of ablative SBRT doses (54–60 Gy in 3–8 fractions) to early-stage NSCLC with local control rates of 85–95% at 3 years (RTOG 0236).
• Head and Neck Cancer: Anatomical changes during a 6–7-week radical head and neck radiotherapy course — including tumour shrinkage, patient weight loss, and parotid gland volume reduction — cause progressive geometric miss of target volumes and overdosing of the spinal cord. Weekly CBCT-based IGRT with adaptive replanning (ART) corrects for these changes, maintaining target coverage and reducing spinal cord dose.
• Left-Sided Breast Cancer: The heart, particularly the left anterior descending coronary artery (LAD), is in close proximity to the left breast radiotherapy field. IGRT using surface-guided radiotherapy (SGRT) to monitor and gate Deep Inspiration Breath-Hold (DIBH) displaces the heart inferiorly and posteriorly during the breath-hold, reducing mean heart dose by 40–50% compared with free breathing — a clinically significant reduction given the long-term risk of radiation-induced cardiac disease (EBCTCG meta-analysis).
• Cervical and Uterine Cancer: The uterus and cervix move substantially with bladder and rectal filling, and tumour shrinkage occurs over the treatment course. IGRT with MRI-based adaptive planning (as in MR-Linac protocols) is the gold standard for brachytherapy target delineation and increasingly for external beam radiotherapy in this site.
• Liver and Pancreas: Tumour motion with respiration and bowel gas movement necessitates IGRT with respiratory gating or abdominal compression for SBRT delivery in hepatocellular carcinoma and metastatic liver disease.
• Brain and Spine — Stereotactic Radiosurgery (SRS): Intracranial SRS (for brain metastases, acoustic neuroma, AVM) uses IGRT with 6-degrees-of-freedom (6-DOF) couch correction and real-time optical surface monitoring (SGRT) to maintain submillimetre positional accuracy throughout single-fraction or hypofractionated treatments.

IGRT is the standard of care for all modern radical external beam radiotherapy courses in most high-income countries, and its benefits are greatest in specific clinical scenarios:

Patients Who Benefit Most from IGRT:

• Tumours in mobile sites with high inter-fraction variation (prostate, lung, liver, cervix, uterus) where daily positional variation exceeds 5 mm and would require large PTV margins without daily verification
• Hypofractionated or stereotactic regimens (SBRT/SABR/SRS) where the biological consequence of a geometric miss is magnified by the high dose per fraction — IGRT is an absolute requirement for safe SBRT delivery
• Tumours adjacent to critical serial structures where late toxicity risk is dose-limiting (prostate near rectum and urethra; brain tumours near brainstem or optic apparatus; thoracic tumours near spinal cord; left breast tumour near heart and LAD)
• Long treatment courses (6–7 weeks) where anatomical changes during treatment — tumour shrinkage, patient weight change, post-obstructive pneumonia resolution — may necessitate adaptive replanning detected through serial IGRT imaging
• Patients who cannot maintain consistent bladder or rectal preparation protocols, making daily position verification particularly important

IGRT System Eligibility: Selection of the IGRT technology depends on the treatment site, available infrastructure, and specific clinical objective: kV CBCT is widely available and appropriate for most sites; SGRT is particularly valuable for left-sided breast DIBH and cranial SRS; Calypso transponders require implantation by a urologist and are specific to prostate; MR-Linac is available only at specialist centres and is used for sites requiring superior soft tissue contrast (cervix, prostate, rectal, pancreas, liver).

IGRT adds approximately 5–15 minutes to each treatment session for imaging acquisition and review. Patients must be able to maintain the treatment position for this additional time. For DIBH techniques, patients must be able to reproducibly sustain a breath-hold of 15–25 seconds — this is assessed during the simulation CT and may be rehearsed using audio-visual biofeedback (Varian RPM, C-Rad Catalyst system).

Multiple IGRT technologies are in clinical use, each with specific advantages, limitations, and optimal applications:

kV Cone-Beam CT (CBCT): The most widely deployed IGRT technology globally. A kilovoltage X-ray source and flat-panel detector mounted perpendicular to the therapeutic beam on the linear accelerator gantry rotate around the patient to acquire a volumetric 3D image (cone-beam CT) in 30–60 seconds. The CBCT is registered to the planning CT using automated image registration algorithms — either bony anatomy registration or soft tissue registration where the tumour or organs at risk are directly matched. Systematic and random position errors are quantified and corrected by automated couch shifts in all three translational dimensions (X, Y, Z) and, with 6-DOF couch capability, in three rotational dimensions. kV CBCT is the standard guidance technique for prostate, head and neck, and abdominal radiotherapy in most centres.

MV Portal Imaging: An older IGRT technique using the megavoltage therapeutic beam itself to produce planar images of the patient's anatomy in two orthogonal directions. MV images have inherently lower soft tissue contrast than kV CBCT but are useful for bony landmark verification and are universally available on all modern linacs. EPID (Electronic Portal Imaging Device) enables rapid 2D verification of bony landmark position.

Fiducial Marker-Based IGRT: Radiopaque gold or platinum markers (typically 3–5 mm cylindrical seeds) are implanted in or near the tumour — typically 3–4 seeds arranged non-colinearly in the prostate gland (implanted transrectally or transperineally by a urologist 2–3 weeks before simulation). On-board kV imaging in two orthogonal planes before each fraction triangulates the 3D position of the markers to track the prostate position independent of rectal and bladder gas interference that reduces CBCT accuracy. Fiducial-based IGRT enables PTV margins of 3–5 mm for the prostate, compared with 7–10 mm without daily imaging.

Calypso GPS for Prostate (Electromagnetic Transponder Tracking): Three radiofrequency transponders (Beacon transponders, Varian Medical) implanted in the prostate are electromagnetically excited by an array positioned above the patient and emit radiofrequency signals that localise the prostate continuously throughout the treatment fraction — enabling real-time intra-fraction prostate motion monitoring. If the prostate moves more than 3 mm from the planned position during beam delivery, the beam is interrupted and the couch adjusted. This is the only clinically available system providing continuous real-time intrafraction tracking without ionising radiation.

Surface-Guided Radiation Therapy (SGRT): High-resolution stereoscopic cameras project structured light patterns onto the patient's skin surface and capture the reflected pattern in real time, creating a 3D surface map that is compared against the reference surface from the simulation CT. Deviations are detected in real time and trigger beam gating when the surface exceeds a tolerance threshold (typically 3–5 mm linear, 1–3 degrees rotational). SGRT is radiation-free and particularly valuable for: (1) intracranial SRS/SRT where it replaces thermoplastic mask-based immobilisation in some protocols and enables submillimetre accuracy; (2) DIBH monitoring for left-sided breast cancer — the patient breathes in to a pre-defined chest wall position held during beam delivery, with the SGRT system gating beam delivery to the breath-hold window; (3) frameless monitoring of patient positioning throughout all treatment fractions as a supplement to CBCT.

MR-Linac: An integrated hybrid device combining a diagnostic-quality MRI scanner (0.35T Unity, Elekta; 1.5T MR-Linac, Viewray MRIdian) with a linear accelerator, enabling soft tissue MRI acquisition before or during each fraction. MR-Linac allows direct tumour visualisation (as opposed to surrogate-based tracking) and enables online adaptive replanning — the treatment plan is reoptimised daily based on the MRI acquired that day (adapt-to-shape workflow), accommodating anatomical changes. This is clinically impactful for rectal cancer (daily tumour regression assessment), cervical cancer, prostate SBRT, and pancreatic stereotactic radiotherapy where CT-based guidance has limited soft tissue contrast.

The integration of daily imaging guidance into radiotherapy delivery has measurably improved the precision, safety, and — in several sites — the therapeutic outcomes of radiation treatment:

• Reduced PTV Margins and Normal Tissue Sparing: The primary dosimetric benefit of IGRT is the ability to reduce PTV safety margins from the 8–15 mm used in conventional 3D-CRT (without daily imaging) to 3–5 mm with CBCT-based IGRT and 2–3 mm with real-time tracking. Smaller margins translate directly to less normal tissue irradiated to high doses, reducing the risk of late toxicity to bowel, rectum, bladder, spinal cord, and heart.
• Dose Escalation: The margin reduction enabled by IGRT allows dose escalation to the tumour without unacceptable increases in normal tissue toxicity. For prostate cancer, randomised trials (PROG 95-09, MRC RT01, CHHiP) demonstrate that dose escalation from 70 Gy to 74–78 Gy improves biochemical failure-free survival, particularly in intermediate-risk disease. IGRT makes dose escalation safe by ensuring the higher dose is reliably delivered to the prostate rather than to the surrounding rectum.
• Hypofractionation and SBRT: IGRT is the enabling technology for hypofractionated and stereotactic regimens that deliver higher doses per fraction over fewer fractions (4–5 fractions for prostate SBRT vs 39 fractions with conventional fractionation). These shorter courses are more convenient for patients, reduce cumulative imaging and treatment time, and may provide radiobiological advantages for tumours with low alpha/beta ratios (prostate, liposarcoma). Validation in landmark trials (PACE-B, HYPO-RT-PC for prostate; RTOG 0236 for lung SBRT) was contingent on robust IGRT.
• Heart Protection in Left-Sided Breast Cancer: SGRT-guided DIBH reduces mean heart dose by an average of 40–53% compared with free-breathing treatment for left-sided breast cancer patients (Bruzzaniti et al., EJMP 2013; Latty et al., J Med Radiat Sci 2015). Given the long-term risk of radiation-induced coronary artery disease (hazard ratio 1.07 per Gy mean heart dose — Darby et al., NEJM 2013), DIBH-IGRT is now standard of care for left-sided breast cancer in most major radiotherapy centres.
• Detection of Setup Errors and Systematic Offsets: IGRT databases captured over multiple fractions enable action level analysis — identification of systematic positioning biases (e.g., a patient consistently set up 5 mm posteriorly) that can be prospectively corrected in subsequent fractions. This continuous quality improvement loop, formalised in protocols such as the shrinking action level (SAL) method, improves the geometric accuracy of the entire treatment course.
• Adaptive Radiotherapy (ART): Serial IGRT imaging provides the dataset needed to detect progressive anatomical changes during a long treatment course (tumour shrinkage, patient weight loss, parotid decompression in head and neck cancer). These changes may require replanning the treatment to maintain target coverage and reduce overdosing of OARs — a process called adaptive radiotherapy (ART). MR-Linac enables online daily ART.

IGRT is a radiotherapy process enhancement rather than a distinct treatment modality, and its risks are generally low relative to its benefits. However, relevant limitations and minor risks should be understood:

• Additional Low-Dose Imaging Radiation: kV CBCT delivers an additional dose of ionising radiation — typically 0.01–0.2 Gy per imaging session depending on the body region, acquisition protocol, and field size. Over a 25–39-fraction course, the cumulative additional dose from daily CBCT guidance is approximately 0.5–5 Gy, distributed across a large volume of tissue. This additional dose is small relative to the therapeutic prescription (45–80 Gy) and is generally considered clinically acceptable given the benefit of precise tumour targeting. SGRT and Calypso tracking are radiation-free. MRI-guidance in MR-Linac adds no ionising radiation but exposes patients to a static magnetic field (0.35–1.5 T).
• Extended Treatment Session Time: Imaging acquisition, automated registration review, and couch correction add approximately 5–15 minutes to each treatment fraction. For patients travelling long distances or with physical difficulty maintaining the treatment position, this prolongation is a practical burden. Advances in CBCT acquisition speed (sub-60-second full volumetric CBCT) and automatic couch correction have reduced this burden substantially.
• Risk of Systematic Error from Incorrect Image Registration: Automated image registration algorithms (deformable and rigid) are highly reliable but not infallible. Over-reliance on automated registration without human review can theoretically result in systematic targeting errors if the algorithm matches to an incorrect anatomical region (e.g., bowel gas misregistered as prostate). Institutional protocols require radiation therapist and physicist review of each CBCT registration before couch correction is applied, minimising this risk.
• Fiducial Marker Complications (Prostate): Transrectal or transperineal fiducial marker implantation carries a small risk of infection (less than 1%), haematuria, haematospermia, and rare rectal bleeding. Marker migration can occur (4–6% of seeds shift more than 2 mm after implantation), reducing the accuracy of marker-based tracking. The Calypso transponder system has a similar implantation risk profile.
• Cost and Technology Access: MR-Linac systems (Unity, MRIdian) have capital acquisition costs of USD 5–10 million, substantially exceeding standard linac costs (USD 2–3 million). The associated physics, dosimetry, and technical staffing requirements are significant. MR-Linac is available at approximately 150–200 centres globally (2025), meaning that most patients worldwide do not have access to this technology. Standard CBCT-based IGRT is far more widely available.

Patients undergoing IGRT are monitored both during the treatment course (on-treatment review) and after its completion (post-treatment follow-up), following site-specific protocols guided by national and international radiotherapy guidelines.

On-Treatment Review (Weekly): Patients are reviewed weekly during treatment by their radiation oncologist or a specialist therapeutic radiographer/radiation therapist. These reviews assess: acute radiation toxicity using validated instruments (RTOG Acute Morbidity Scoring Criteria; CTCAE Version 5.0); patient weight, nutritional status, and hydration (particularly important in head and neck patients); bladder and bowel preparation compliance (relevant to prostate and gynaecological IGRT); and IGRT image review to identify systematic setup trends or anatomical changes (such as significant tumour shrinkage or rapid weight loss) that may necessitate treatment replanning.

Post-Treatment Follow-Up — Prostate Cancer: PSA monitoring is the primary surveillance tool after radical radiotherapy for prostate cancer. PSA nadir is typically reached 18–24 months after completion of radiotherapy. Biochemical failure (BCR) is defined by the Phoenix definition: PSA rise of 2 ng/mL above nadir. Follow-up schedule: every 3–6 months for the first 2 years, then every 6 months for years 2–5, then annually thereafter. PSMA-PET CT is used for salvage staging at biochemical recurrence.

Post-Treatment Follow-Up — Lung Cancer (SBRT): CT thorax with contrast is performed at 4–6 weeks post-SBRT, then at 3-monthly intervals for the first 2 years. Radiological assessment must distinguish post-SBRT fibrosis (a normal post-treatment change occurring in 50–70% of patients) from local recurrence — a challenging distinction that may require PET-CT or serial imaging to characterise.

Post-Treatment Follow-Up — Breast Cancer: Annual bilateral mammography (or ipsilateral mammography and MRI if implants are present). Clinical review at 6-monthly intervals for 2–3 years, then annually. Assessment for late radiation effects including radiation pneumonitis (2–3% with modern techniques), brachial plexopathy (very rare with modern dosimetry), and cardiac toxicity (echo or CTCA in patients with cardiac risk factors who received left-sided RT).

Dosimetric Review During Treatment (IGRT Data Analysis): Medical physicists perform weekly review of IGRT correction data to assess systematic setup errors and adjust action levels if persistent offsets are detected. Cumulative dose reconstruction from daily CBCT images enables delivered dose verification, increasingly available on modern linac platforms.

IGRT adds cost to radiotherapy delivery primarily through the capital and operational costs of imaging hardware, extended treatment session time, additional physics and quality assurance activities, and (in the case of fiducial markers and Calypso transponders) implantation procedures. Cost varies significantly by country, technology level, and payer system.

• Technology Level: The incremental cost of IGRT depends on the system used. Standard kV CBCT is now included in the cost of modern linac systems and adds minimal marginal cost per fraction. SGRT (AlignRT, Catalyst) requires capital investment of approximately USD 200,000–400,000 per unit plus maintenance, with negligible per-fraction incremental cost once installed. Calypso transponders add approximately USD 1,500–2,000 per patient for the transponder cost plus the implantation procedure fee. MR-Linac represents a substantially higher investment — capital cost of USD 5–10 million per system — reflected in higher per-fraction treatment costs at centres with this technology.
• Reimbursement (United States): CPT codes for IGRT (77387 — guidance for localisation using imaging, per treatment session) added a daily IGRT reimbursement of approximately USD 25–40 per fraction under Medicare technical component in the hospital outpatient setting (2025 Medicare fee schedule). Image-guided SBRT courses (e.g., lung SBRT 54 Gy/3 fractions) are reimbursed at substantially higher levels than conventional fractionation due to planning complexity and stereotactic codes.
• Number of Fractions: Total IGRT imaging cost scales with the number of treatment fractions. A 39-fraction course (conventional prostate fractionation) incurs more cumulative imaging cost than a 5-fraction SBRT course. The shift toward hypofractionation — enabled and validated by IGRT — paradoxically reduces overall treatment programme cost by reducing the number of treatment sessions, transportation visits, and linac slot usage.
• Country Variation: In the United Kingdom, IGRT is funded within NHS radiotherapy tariffs for indicated courses; no additional patient charge applies. In India, IGRT-capable radiotherapy is available at major cancer centres (Tata Memorial, AIIMS, Apollo, Manipal) at costs ranging from INR 150,000 to INR 600,000 for a complete course depending on technique and fractionation. In Singapore, a complete IGRT-IMRT course for prostate cancer costs approximately SGD 20,000–50,000.

IGRT is an enhancement of external beam radiotherapy delivery rather than a standalone treatment modality. The relevant comparators are therefore other radiotherapy delivery techniques and radiation modalities:

• Conventional 3D Conformal Radiotherapy (3D-CRT) Without IGRT: Treatment planning based on static simulation CT with fixed immobilisation and bony landmark alignment at each fraction, without daily imaging verification. The historical standard before IGRT adoption, requiring larger PTV margins (8–15 mm) to compensate for unverified positional uncertainty. Associated with higher rates of rectal toxicity at dose-escalated prostate doses (demonstrated in randomised dose-escalation trials) compared with IGRT-facilitated IMRT. Remains appropriate for palliative radiotherapy courses where precision is less critical and session efficiency is prioritised.
• Intensity-Modulated Radiation Therapy (IMRT) Without IGRT: IMRT creates highly conformal dose distributions with sharp dose gradients using modulated multi-leaf collimator beams, enabling better dose painting to irregular tumour volumes and avoidance of adjacent OARs. However, without IGRT, the sharp dose gradients that protect OARs may also result in geographic miss of the tumour if positioning errors are not corrected. Modern clinical practice pairs IMRT with IGRT for radical radiotherapy courses — the two technologies are complementary, not alternatives.
• Proton Therapy: Uses protons rather than photons to deliver radiation, exploiting the Bragg peak physical dose deposition pattern — a sharp dose fall-off at the end of the proton range — to spare tissue distal to the tumour. Proton therapy is inherently more sensitive to range uncertainties and anatomical changes than photon radiotherapy, making IGRT (and adaptive planning) even more critical in proton therapy, not less. Proton IGRT uses CT-on-rails or in-room CBCT. Proton therapy has demonstrated benefit in specific tumour sites (paediatric brain tumours, base of skull tumours, uveal melanoma) and is under active RCT investigation in prostate, lung, and head and neck cancers.
• Adaptive Radiation Therapy (ART): An extension of IGRT that goes beyond positional correction to full plan reoptimisation during the treatment course based on changes in tumour and normal tissue anatomy detected through serial imaging. Online ART (replan and treat within the same session, as in MR-Linac workflows) and offline ART (replan between fractions) are both in clinical use. ART is most impactful in tumour sites with rapid anatomical changes — head and neck cancer, cervical cancer, and rectal cancer. ART is complementary to IGRT and represents its logical evolution.
• Brachytherapy: Internal radiotherapy in which radioactive sources are placed directly in or adjacent to the tumour — bypassing external beam positioning challenges entirely. For prostate cancer, low-dose-rate (LDR) brachytherapy (permanent iodine-125 seed implant) and high-dose-rate (HDR) brachytherapy (temporary iridium-192 source) deliver highly conformal dose distributions without the inter-fraction motion challenges that IGRT addresses. HDR brachytherapy combined with EBRT IGRT is the current standard of care for high-risk and locally advanced prostate cancer per GEC-ESTRO and ABS guidelines.